May 06, 2025 4:01pm EDT Rigel Reports First Quarter 2025 Financial Results and Provides Business Update
Apr 29, 2025 8:05am EDT Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update
Mar 27, 2025 8:05am EDT Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation
Mar 04, 2025 4:01pm EST Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Feb 25, 2025 8:05am EST Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update
Jan 22, 2025 8:05am EST Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease
